SCHEMBL2007225

SCHEMBL2007225

COC(=O)Cc1ccc(Oc2ccc3c(cc(C(F)(F)F)n3C(=O)O)c2[N+](=O)[O-])c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.37
ALDH1A1 P00352 5/20 0.36
LMNA P02545 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
HPGD P15428 3/20 0.36
MAPT P10636 3/20 0.35
CASP7 P55210 1/20 0.35
CASP6 P55212 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
PTGDR Q13258 2/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
KMT2A Q03164 1/20 0.35
AKR1C3 P42330 1/20 0.34
HTT P42858 2/20 0.34
TSHR P16473 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12570811 0.90 MTNR1A (0.36) TTRALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL2004270 0.86 TTR (0.39) TTRALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL12570813 0.79 MTNR1A (0.37) TTRALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL12570809 0.78 PTGDR (0.43) TTRALDH1A1LMNAMAPTCASP7
SCHEMBL2010090 0.73 FBP1 (0.43) TTRALDH1A1LMNAHPGDMAPT
SCHEMBL2012915 0.73 ALDH1A1 (0.46) TTRALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL14015527 0.72 MAPT (0.42) TTRALDH1A1LMNAHPGDMAPT
SCHEMBL2006831 0.72 MAPT (0.46) TTRALDH1A1LMNAMAPTCASP7
SCHEMBL14014555 0.72 LMNA (0.43) TTRALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL2000722 0.71 ALDH1A1 (0.37) TTRALDH1A1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164828-B1 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC (US) 2013-03-27 EP disclosed
US-7960567-B2 Compounds and methods useful for treating asthma and allergic inflammation AMGEN INC. (US) 2011-06-14 US disclosed
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION CCL11, LTC4S, TSLP TTR 4580/4885ALDH1A1 495/4885LMNA 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.